RxDoctor Payments Data

Tara Breslin, PA

Medical · Hartford, CTNPI 1710093869

Payments from drug & device makers

$3,367in general payments, 2019–2025

Across 101 payments — averaging $33.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$1K
  • Sumitomo Pharma America, Inc.$520
  • Astellas Pharma US Inc$298
  • C. R. Bard, Inc. & Subsidiaries$233
  • Ferring Pharmaceuticals Inc.$195
  • Antares Pharma, Inc.$122
  • plus $968 from 20 others

What the payments were for

  • Travel & lodging$49915%
  • Food & beverage$2,72681%
  • Education$1424%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,367 in reported general payments places this provider in the 85th percentile of 592 medical providers in Connecticut.

See all medical providers in Connecticut

Medicare billing

Part B allowed, 2024
$23,162
Medicare patients
180
Services billed
402

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron189$201,080
MyrbetriqMirabegron109$85,569
Mirabegron ErMirabegron23$17,308
XyostedTestosterone Enanthate19$15,393
Solifenacin Succinate72$6,646
Estradiol47$3,942
Tadalafil19$3,895
Tamsulosin Hcl228$2,797
Methenamine Hippurate44$2,561
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst121$2,241
Fosfomycin Tromethamine11$1,335
Silodosin12$1,183
Potassium Citrate ErPotassium Citrate16$1,006
Alfuzosin Hcl ErAlfuzosin Hcl47$953
Finasteride94$809

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$520$201,080189 claims
Astellas Pharma US IncMyrbetriq$298$85,569109 claims
Antares Pharma, Inc.Xyosted$122$15,39319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 592 medical providers in Connecticut.

Other medical in Hartford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →